TD Cowen Issues Pessimistic Forecast for Zoetis (NYSE:ZTS) Stock Price

Zoetis (NYSE:ZTS) had its price target cut by TD Cowen from $150.00 to $104.00 in a report released on Tuesday,Benzinga reports. The firm currently has a “buy” rating on the stock. TD Cowen’s price target would indicate a potential upside of 44.08% from the stock’s current price.

Other research analysts have also issued reports about the company. Leerink Partners reissued a “market perform” rating on shares of Zoetis in a report on Tuesday, March 10th. JPMorgan Chase & Co. decreased their target price on shares of Zoetis from $190.00 to $130.00 and set an “overweight” rating for the company in a research report on Friday, May 8th. Weiss Ratings lowered Zoetis from a “sell (d+)” rating to a “sell (d)” rating in a research note on Friday, June 12th. William Blair reaffirmed an “outperform” rating on shares of Zoetis in a report on Monday, March 2nd. Finally, UBS Group decreased their price target on Zoetis from $130.00 to $99.00 and set a “neutral” rating for the company in a report on Friday, May 8th. Seven investment analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $130.85.

Zoetis Stock Performance

Shares of Zoetis stock opened at $72.18 on Tuesday. The company has a market capitalization of $30.26 billion, a PE ratio of 12.01, a P/E/G ratio of 1.19 and a beta of 0.75. The company has a 50-day simple moving average of $87.78 and a two-hundred day simple moving average of $110.59. Zoetis has a one year low of $72.38 and a one year high of $161.77. The company has a debt-to-equity ratio of 2.80, a quick ratio of 1.91 and a current ratio of 3.15.

Zoetis (NYSE:ZTS) last posted its quarterly earnings data on Thursday, May 7th. The company reported $1.53 earnings per share for the quarter, missing analysts’ consensus estimates of $1.60 by ($0.07). Zoetis had a return on equity of 66.85% and a net margin of 27.80%.The business had revenue of $2.26 billion during the quarter, compared to analyst estimates of $2.30 billion. During the same period in the previous year, the business earned $1.48 EPS. The firm’s revenue for the quarter was up 2.9% compared to the same quarter last year. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. Research analysts expect that Zoetis will post 6.88 EPS for the current fiscal year.

Insider Activity at Zoetis

In other news, Director Paul Bisaro acquired 2,000 shares of the firm’s stock in a transaction on Wednesday, May 13th. The shares were bought at an average price of $75.88 per share, for a total transaction of $151,760.00. Following the acquisition, the director owned 27,862 shares of the company’s stock, valued at approximately $2,114,168.56. This trade represents a 7.73% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director Frank A. Damelio purchased 6,650 shares of the stock in a transaction that occurred on Wednesday, May 13th. The shares were acquired at an average price of $75.39 per share, for a total transaction of $501,343.50. Following the completion of the transaction, the director directly owned 21,458 shares of the company’s stock, valued at $1,617,718.62. The trade was a 44.91% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. In the last ninety days, insiders bought 11,650 shares of company stock valued at $886,384. 0.22% of the stock is owned by insiders.

Hedge Funds Weigh In On Zoetis

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Global Wealth Strategies & Associates purchased a new stake in shares of Zoetis in the fourth quarter valued at about $25,000. Prosperity Bancshares Inc acquired a new stake in Zoetis during the fourth quarter worth $25,000. KERR FINANCIAL PLANNING Corp acquired a new stake in Zoetis during the third quarter worth $31,000. Cassaday & Co Wealth Management LLC purchased a new stake in Zoetis in the first quarter valued at $28,000. Finally, Lodestone Wealth Management LLC acquired a new position in shares of Zoetis in the 4th quarter valued at $30,000. Institutional investors and hedge funds own 92.80% of the company’s stock.

About Zoetis

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.